Remote controlled capsules in human drug absorption (HDA) studies.
The biopharmaceutical complexity of today's new drug candidates provides significant challenges for pharmaceutical scientists in terms of both candidate selection and optimizing subsequent development strategy. In addition, life cycle management of marketed drugs has become an important income stream for pharmaceutical companies, but the selection of least risk/highest benefit strategies is far from simple. The proactive adoption of human drug absorption (HDA) studies using remote controlled capsules offers the pharmaceutical scientist significant guidance for planning a route through the maze of product development. This review examines the position of HDA studies in drug development, using a variety of case histories and an insightful update on remote controlled capsules to achieve site-specific delivery.
Wilding
Ian R
IR
Pharmaceutical Profiles Ltd., Ruddington Fields, Ruddington, Nottingham, UK. iwilding@pharmaprofiles.co.uk
Prior
David V
DV
D002214:Capsules; D003692:Delayed-Action Preparations; D006801:Humans; D007408:Intestinal Absorption; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism; D010599:Pharmacokinetics; D011877:Radionuclide Imaging; D013678:Technology, Pharmaceutical / Q000379:methods
D002214:Capsules; D003692:Delayed-Action Preparations; D004364:Pharmaceutical Preparations